

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VOLUNTARY ANNOUNCEMENT DRUG REGISTRATION APPROVAL OF “NICORANDIL FOR INJECTION”**

This announcement is made by Tianda Pharmaceuticals Limited (the “**Company**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company and potential investors informed of the latest business development of the Company and Tianda Pharmaceuticals (Yunnan) Ltd (“**Pharmaceuticals Yunnan**”), a wholly owned subsidiary of the Company.

Pharmaceuticals Yunnan has been granted the drug registration approval of “Nicorandil for Injection” (the “**Product**”) by the National Medical Products Administration of the People’s Republic of China.

The Product is a type of lyophilized powder for injection with main ingredient being nicorandil, and is mainly used for the treatment of acute coronary syndromes such as unstable angina. Nicorandil is a first-tier drug for coronary microvascular angina. It can effectively dilate coronary arteries and has a rapid onset of action. It has been included in the “Guidelines for Rational Drug Use in Coronary Heart Disease (2nd Edition)” and “Guidelines for Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndrome” and “Guidelines for Rational Drug Use in ST Segment Elevation Myocardial Infarction” and other treatment guidelines.

The Product is registered under type 3 chemical drug and is regarded as passing the consistency evaluation upon receiving the drug registration approval. The Product will further enrich and improve the Company’s product portfolio and strengthen the Company’s advantages in cardiovascular and cerebrovascular fields. After years of R&D investment, the Company’s R&D has entered the harvest period. Including nicorandil for injection, a total of 7 new varieties are expected to be launched in 2024 and 2025, laying a solid foundation for future steady development.

By order of the Board  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 16 May 2024

*As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.*